Consensus Solventum Corporation London S.E.

Stocks

0AD1

US83444M1018

Medical Equipment, Supplies & Distribution

Market Closed - London S.E. 09:31:50 2026-07-28 EDT			After hours 15:59:49
83.10 ^USD	+11.36%		87.74	+5.58%

09-09	Solventum Corporation Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-09-2026 10:15 AM
08-06	Stifel Adjusts Price Target on Solventum to $100 From $90	MT

1a96270ca38da07251d6.c49oe0eg8GMaB5rd2gDc3o6e3WVgpyD_1J6zG2mSkw0.J_lYLjP3mFNqcO6LlXaXjc3O6DQ24UeZne3wSCD25FgF3gczNOahMyk1yw~522ac07af2ff8ef6a099b5afe9d8e407

Analysts' recommendations: Solventum Corporation

08-06	Stifel Adjusts Price Target on Solventum to $100 From $90	MT
08-06	KeyBanc Adjusts Price Target on Solventum to $102 From $93	MT
08-06	Mizuho Securities Adjusts Solventum Price Target to $113 From $100	MT
08-06	BTIG Research Adjusts Solventum Price Target to $95 From $91	MT
08-06	Jefferies & Co. Adjusts Solventum Price Target to $95 From $79	MT
08-06	Piper Sandler Adjusts Solventum Price Target to $105 From $92	MT
08-06	BMO Capital Adjusts Solventum Price Target to $84 From $81	MT
08-06	UBS Adjusts Price Target on Solventum to $101 From $95, Maintains Buy Rating	MT
08-06	Wedbush Adjusts Price Target on Solventum to $101 From $94, Maintains Outperform Rating	MT
07-28	UBS Upgrades Solventum to Buy From Neutral, Adjusts Price Target to $95 From $78	MT
07-13	BTIG Adjusts Solventum Price Target to $91 From $89, Maintains Buy Rating	MT
07-09	BMO Capital Initiates Coverage on Solventum With Market Perform Rating, $81 Price Target	MT
05-27	Goldman Sachs Adjusts Price Target on Solventum to $67 From $66, Maintains Sell Rating	MT
05-15	Solventum Seen Positioned for Meaningful Re-Rating Over Next 12 to 18 Months, Wedbush Says	MT
05-15	Wedbush Initiates Solventum at Outperform With $94 Price Target	MT
05-06	UBS Adjusts Price Target on Solventum to $78 From $82, Maintains Neutral Rating	MT
05-06	Analyst recommendations: AMD, KKR, PayPal Holdings, Arista Networks, and TransDigm Group.
04-27	KeyBanc Adjusts Price Target on Solventum to $92 From $99, Maintains Overweight Rating	MT
04-17	Piper Sandler Adjusts Solventum PT to $92 From $98, Maintains Overweight Rating	MT
04-13	BTIG Research Adjusts Solventum Price Target to $89 From $100, Maintains Buy Rating	MT
04-08	Goldman Sachs Adjusts Solventum Price Target to $66 From $72, Maintains Sell Rating	MT
03-24	Rothschild & Co Redburn Initiates Solventum at Sell, With $60 Price Target	MT
03-02	UBS Adjusts Solventum Price Target to $82 From $79, Maintains Neutral Rating	MT
02-27	KeyBanc Adjusts Price Target on Solventum to $99 From $97, Maintains Overweight Rating	MT
02-27	Wells Fargo Adjusts Price Target on Solventum to $83 From $86, Maintains Equalweight Rating	MT

More recommendations

Other Medical Equipment, Supplies & Distribution

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ABBOTT LABORATORIES					+21.69%
	MEDTRONIC PLC					+21.49%
	STRYKER CORPORATION					+33.56%
	ESSILORLUXOTTICA					+59.76%
	CENCORA, INC.					+22.98%
	BECTON, DICKINSON AND COMPANY					+9.31%
	HOYA CORPORATION					+28.07%
	IDEXX LABORATORIES, INC.					+34.31%
	DEXCOM, INC.					+9.49%
	Average					+26.74%
	Weighted average by Cap.					+27.51%